Should I buy or sell Cingulate stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares. View CING analyst ratings or view top-rated stocks .

What is Cingulate's stock price target for 2024?

3 brokers have issued 1 year target prices for Cingulate's shares. Their CING share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 917.8% from the stock's current price. View analysts price targets for CING or view top-rated stocks among Wall Street analysts .

How have CING shares performed in 2024?

Cingulate's stock was trading at $7.65 at the beginning of the year. Since then, CING stock has decreased by 89.7% and is now trading at $0.7860. View the best growth stocks for 2024 here .

When is Cingulate's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CING earnings forecast .

When did Cingulate's stock split?

Cingulate's stock reverse split on the morning of Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Cingulate IPO?

Cingulate (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share.

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CING

Cingulate (CING) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free CING Stock Alerts

$0.79

-0.14 (-15.12%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.75
▼
$0.98
50-Day Range: $0.79
▼
$1.35
52-Week Range: $0.75
▼
$23.80

Volume: 239,034 shs
Average Volume: 335,134 shs
Market Capitalization: $3.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Cingulate alerts:

Cingulate MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 917.8% Upside
$8.00 Price Target
Short Interest: Healthy
1.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$1,490 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.36 out of 5 stars

3.2

Analyst's Opinion

Consensus Rating
Cingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cingulate has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.21% of the float of Cingulate has been sold short.
Short Interest Ratio / Days to Cover
Cingulate has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cingulate has recently decreased by 2.81%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cingulate does not currently pay a dividend.
Dividend Growth
Cingulate does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CING.

1.5

News and Social Media Coverage

News Sentiment
Cingulate has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cingulate this week, compared to 2 articles on an average week.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cingulate insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,490.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
38.43% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Cingulate is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cingulate is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Cingulate Stock (NASDAQ:CING)

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CING Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CING Stock News Headlines

April 1, 2024 | bizjournals.com

Cingulate CEO talks about the pharmaceutical company's road ahead after tough 2023

April 1, 2024 | globenewswire.com

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 28, 2024 | yahoo.com

5 Easy Secrets of Super Agers That Can Help You Live a Long and Happy Life

March 20, 2024 | bizjournals.com

Cingulate can add $3.5M to latest stock offering as it navigates FDA drug approval

March 19, 2024 | globenewswire.com

Cingulate to Participate in Benzinga All Live Access Event

March 13, 2024 | msn.com

ADHD linked to unusual brain connectivity patterns in large-scale neuroimaging study

March 13, 2024 | msn.com

Breakups Can Actually Change Your Brain Chemistry—Here's How

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 12, 2024 | nz.news.yahoo.com

Why you can't focus and what science says can help

March 12, 2024 | sg.news.yahoo.com

Here's why you can't focus - and science-backed ways to help you

March 11, 2024 | msn.com

Self-hypnosis is soaring in popularity RN - I tried it after hearing that it could boost your mood and mental health from home

March 6, 2024 | globenewswire.com

Cingulate to Attend DCAT Week 2024 in New York City

February 28, 2024 | bizjournals.com

Cingulate regains compliance with Nasdaq, maintaining key capital source

February 25, 2024 | msn.com

Using deep brain stimulation to map dysfunctional brain circuits linked to four disorders

February 22, 2024 | foxnews.com

New York woman reports improved mental health after undergoing brain electrode therapy

February 22, 2024 | msn.com

Brain Pacemaker? New Stimulation Device Tested to Treat Depression Shows Promising Results

February 22, 2024 | msn.com

Researchers use deep brain stimulation to map therapeutic targets for four brain disorders

February 22, 2024 | msn.com

Woman Says Experimental Brain Implant Helped Her Lifelong Depression: 'Continuous Prozac'

February 21, 2024 | dailymail.co.uk

A pacemaker for the brain helped a woman with crippling depression. It may soon be available to more

February 18, 2024 | msn.com

Additional study shows promise for low-intensity ultrasound as a non-invasive approach to alleviate pain

February 14, 2024 | bizjournals.com

Cingulate adds three new members to board, following exits in December

February 14, 2024 | msn.com

Maltreatment linked to altered brain structure and spontaneous thought patterns in children, study finds

February 13, 2024 | finance.yahoo.com

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

February 8, 2024 | bizjournals.com

Pharma company Cingulate raises $7.5M from public offering

February 6, 2024 | markets.businessinsider.com

Cingulate Announces Closing of $7.5 Million Public Offering

February 5, 2024 | msn.com

Bullied teens' brains show chemical change associated with psychosis

See More Headlines

Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/16/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CING
CUSIP: N/A
CIK: 1862150
Web: www.cingulate.com
Phone: 913-942-2300
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +917.8%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($32.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,530,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -432.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.06
Quick Ratio: 0.06

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($5.88) per share
Price / Book: -0.13

Miscellaneous

Outstanding Shares: 5,010,000
Free Float: 3,085,000
Market Cap: $3.94 million
Optionable: Not Optionable
Beta: -0.95

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Shane J. Schaffer Pharm.D. (Age 48)
PharmD, CEO, Principal Financial Officer & Chairman of the Board
Comp: $491.96k
Dr. Laurie A. Myers M.B.A. (Age 66)
Ph.D., Executive VP & COO
Comp: $415.17k
Dr. Matthew N. Brams M.D. (Age 59)
Executive VP & Chief Medical Officer
Comp: $244.79k
Ms. Jennifer L. Callahan CPA (Age 53)
CFO, Senior VP & Corporate Controller
Dr. Raul R. Silva M.D. (Age 65)
Executive VP & Chief Science Officer
Thomas Dalton
Head of Investor & Public Relations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

CING Stock Analysis - Frequently Asked Questions

Should I buy or sell Cingulate stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares.
View CING analyst ratings or view top-rated stocks.
What is Cingulate's stock price target for 2024?: 3 brokers have issued 1 year target prices for Cingulate's shares. Their CING share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 917.8% from the stock's current price.
View analysts price targets for CING or view top-rated stocks among Wall Street analysts.
How have CING shares performed in 2024?: Cingulate's stock was trading at $7.65 at the beginning of the year. Since then, CING stock has decreased by 89.7% and is now trading at $0.7860.
View the best growth stocks for 2024 here.
When is Cingulate's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CING earnings forecast.

When did Cingulate's stock split?: Cingulate's stock reverse split on the morning of Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
When did Cingulate IPO?: Cingulate (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share.
How do I buy shares of Cingulate?: Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CING) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cingulate (CING) Stock Price, News & Analysis

Cingulate MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Cingulate Stock (NASDAQ:CING)

CING Stock Price History

CING Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

CING Stock Analysis - Frequently Asked Questions

Overall MarketRank^™